Get started

ZIOP

ZIOPHARM ONCOLOGY INC. - NASDAQ: $ZIOP Building BaseAfter recapturing its 200 DMA back in March and subsequently vaulting from a 3 to 4 - handle, ZIOPHARM ONCOLOGY INC - NASDAQ:ZIOP has found itself in a sideways drift and appears to be building a base these past couple of months as we can observe from the Daily chart above. With the stock trading above all of its important moving averages 20/50/200 DMA's, ZIOP remains in a favorable technical posture as the base building process continues to develop. In addition, if one were to zoom-out to both the Weekly and Monthly time-frames, we can also see that ZIOP may just be in the process of building-out a potential inverted H&S pattern and should such development materialize and complete, the longer-term measured move implies an initial $8 objective. Moving forward, if and when at any time in the days/weeks ahead ZIOP is capable of clearing the $4.85 figure and perhaps more importantly the $5 level, such occurrence would likely suggest that higher levels are in the offing. Thus, both investors/traders may want to continue to monitor the action closely moving forward.
Z
by InsiderFinancial
NEXT WEEK'S COVERED CALL CANDIDATES: ZIOP, NVAX, LC, WLLHere's my "short list" for covered call candidates for next week generated by looking at Barcharts.com high volatility stock options list and the Dough grid: WLL buy shares at 7.66; sell Sept 16th 8 call; 7.10 debit; $90 max profit (12.7% ROC) CC buy shares at 11.45; sell Sept 16th 12 call; 10.78 debit; $122 max profit (10.6% ROC) LC buy shares at 5.40; sell Oct 21st 5.5 call; 4.85 debit; $65 max profit (13.4% ROC) ZIOP buy shares at 5.46; sell Oct 21st 6 call; 4.65 debit; $135 max profit (29.0% ROC) NVAX buy shares at 7.04; sell Oct 21st 8 call; 5.42 debit.; $258 max profit (47.6% ROC) FCX buy shares at 11.92; sell Sept 30 12 call; 10.90 debit; $102 max profit (9.3% ROC) JCP buy shares at 10.55; sell Sept 30th 11 call; 9.59 debit; $96 max profit (9.6% ROC) Notes: (1) WLL's a petro play. Because so many small petro companies are in trouble of one kind or another (i.e., shale and/or offshore oil exploration exposure), I generally prefer playing something with a little less "single company exposure" (e.g., XOP). But, hey, it meets my general rule of >10% ROC. (2) CC is a basic materials/chemical play. It spun off from DuPont and has had quite an up run here in spite of a recent punitive damages judgment for chemical dumping (weirdly, the stock dipped and then subsequently popped on the news, probably out of relief that the debacle was in the rear view mirror). (3) LC's been in a downtrend since IPO. At best, a money, take, run play. (4) I still like ZIOP. It's biopharma and has a fairly diverse pipeline such that if one drug fails, they still have more in the hopper. And that 29% ROC, well ... drop dead gorgeous if it can get to $6. (5) I'm also in NVAX (biopharm). In comparison to ZIOP, their pipeline is quite narrow and currently devoted to a single vaccine (RSV). sg.finance.yahoo.com (vaccine "could be breakthrough," but not time to "break out the champagne" (code for "it could suck ... or not")). (6) FCX (mining). I covered called this in late 2015, early 2016 which commodities were at a cyclical low and then bailed out when it appeared to be topping. Looking back, it kind of looks pricey here in comparison, and I'm not so hot on the ROC. However, it's highly liquid, and it has some room to pop to 14.00 resistance (and naturally some room to cave; the 2016 low is sub-$4). (7) JCP. Well, it's JCP. Plus, it's had a bit of a run up here, and if past performance is indicative of future results, well, it could zombie trade back to sub-$9 and with the ROC, well, not at the top of my list ... .
WLong
by NaughtyPines
DSKX Begins To Rally After The Conference CallShares of DSKX continues to rally from last week after they held a conference call to discuss the recently announced agreement to acquire Radiancy, Inc., a leading developer of consumer medical devices and the Neova® dermatological products. It appears investors are beginning to notice the financial value this new deal brings and the future outlook of the company, so if you haven't already, I highly encourage you to listen to today's conference call as soon as possible. Much larger company structure overall, significant increase in revenue, assets, cash flow and working capital with a very reputable management team to move the company forward. The fact that the current market cap is only 33M is what really gets me excited. Listen to the call to learn more: The replay of the conference call can be heard by dialing 1-888-286-8010 in the United States and Canada or +1-617-801-6888 internationally, then referencing the Conference Passcode "56187013" A recording of the call can also be heard on the company website. In the call, the DS Healthcare Group management team shared their motivations and answered questions relating to the business fundamentals on the Radiancy & Neova® deal, explaining how natural strategy alignment and synergies will lead to significant bottom line contribution. The call was hosted by Mark Brockelman (CFO), Manny Gonzeles (CCO) and Renee Barch-Niles (CEO) and took place on Thursday, February 25th, 2016, at 8:30 a.m. EST. -Renee Barch-Niles (CEO), an experienced CPG Executive who drove double-digit year-over-year growth in global food, drug, mass, club and specialty channels for Global companies such as Daymon Worldwide and Emilia Personal Care. -Mark Brockelman (CFO) who has great experience in mergers and acquisitions, systems integration expertise and highly astute financial acumen. Mr. Brockelman Brockelman served as the Chief Financial Officer for National Dentex Corporation as well as the Senior Vice President/Chief Financial and Administrative Officer of the Miami Dolphins. -Manny Gonzalez (CCO), a former top (NASDAQ: PG) Procter & Gamble executive managing a team of 7,000 sales representatives in the U.S., who has direct access to every major retailer in the country. Acquisition Press Release Below: finance.yahoo.com For full disclose please visit: www.stockpicksnyc.com
DLong
by StockPicksNYC
ZIOP Long: Alternate Bat and Trendline BreakZIOP has completed an alternate bat pattern. The pattern completion is confluent with a .886 fib level on a higher TF structure low to structure high. A trendline was broken and retested on 12/22, indication of possible upcoming bullish movement at the PRZ. A second trendline was broken today, which may be an opportunity to catch the breakout toward .382CD. Entry is placed at the alternate bat PRZ with target at .382CD and SL below structure lows. Look for heavier volume within the next couple of candles.
ZLong
by glennmercer